https://www.thebodypro.com/category/first-line-hiv-treatment/tag/conference-coverage
First-Line HIV Treatment

Conference Coverage

The Latest

Promo Image

ATAZIP: Switching Away From Lopinavir/Ritonavir

Switching between protease inhibitors (PIs) may lead to improved dosing frequency, better management of gastrointestinal and lipid toxicity and a reduction in ritonavir (RTV, Norvir) exposure levels. The SWAN study1 was the largest study to evaluate ...

Promo Image

Darunavir Matches, and in Some Patients Outperforms, Lopinavir/Ritonavir as Second-Line and Third-Line Treatment

Darunavir (TMC114, Prezista) is the first engineered protease inhibitor (PI) designed specifically to overcome PI-resistant mutations. At the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007), several ...

Promo Image

New Developments in the Management of HIV Treatment-Naive Patients

Introduction Assessment of Several Once-Daily, First-Line Regimens Using Viral Decay to Assess the Efficacy of Treatment The Problem of Primary Resistance: Prevalence and Clinical Implications Footnotes

Introduction

The first antiretrovir...

Promo Image

Emergence of Drug Resistance and First-Line Combination Therapy in the Swiss HIV Cohort Study

Viktor von Wyl and colleagues1 looked at the Swiss Cohort to examine the emergence of antiretroviral resistance after patients began their first antiretroviral regimen that included either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a...

Promo Image

Strategic Use of Antiretroviral Therapy: What to Use and When?

What is the current state of the art in HIV treatment? A comprehensive talk given by Dr. Sharon Riddler1 from the University of Pittsburgh tried to answer this question focusing on the timing and type of HIV treatment appropriate for treatment-naive ...

Promo Image

Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain

STUDY SNAPSHOTDesign:Substudy of the open-label, randomized study BMS097 (SWAN) to determine the safety and efficacy of a switch from lopinavir/ritonavir to atazanavir in virologically suppressed patients.Population:153 individuals on lopinavir/riton...

Promo Image

Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy

Current U.S. Department of Health and Human Services guidelines1 recommend lopinavir/ritonavir (LPV/r, Kaletra) in combination with lamivudine (3TC, Epivir) or emtricitabine (FTC, Emtriva) and zidovudine (AZT, Retrovir) as a first-line regimen for tr...

Promo Image

Efavirenz-Based Regimens Best Lopinavir/Ritonavir Regimens in Head-to-Head Trial

Traditionally, an antiretroviral therapy regimen has consisted of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus a third drug, either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). The ...

Promo Image

SMART & Staccato: Two CD4-Guided Treatment Interruption Trials With Contradictory Results

Introduction

While the value of highly active antiretroviral therapy (HAART) for the management of HIV infection and AIDS has been proven in many clinical trials in all parts of the world, one of the most basic strategic questions of HIV management ...

Promo Image

Study: No Advantage to Adding Fourth Drug to AIDS Cocktail

A three-year study of 765 patients has found no advantage in adding a fourth drug to the standard three-drug cocktail for treating newly diagnosed HIV patients.

"Triple drug treatment has been the standard approach to treatment of HIV infection for ...